Lawyers for Pancreatic Cancer from Januvia, Janumet
Marc J. Bern & Partners and its professional team are reviewing potential lawsuits for individuals diagnosed with cancer or other injuries that may have been caused by the popular type 2 diabetes drugs Januvia or Janumet.
Research has suggested that side effects of Januvia may increase the risk of damage to the pancreas and chronic pancreatitis, which may ultimately lead to the development of pancreatic cancer.
It appears that Merck & Co. withheld important information about the risk of health problems from Januvia and Janumet. As a result, financial compensation may be available through a Januvia cancer lawsuit for individuals diagnosed with:
- Pancreatic Cancer
- Thyroid Cancer
- Hemorrhagic or Necrotizing Pancreatitis
- Kidney Failure
- Wrongful Death
Potential cases are being reviewed on behalf of individuals throughout the United States, and there are no fees or expenses unless a recovery is obtained. Request a free consultation and claim evaluation.
Januvia Problems and Janumet Problems
Januvia (sitagliptin) was approved in October 2006 as the first in a new class of diabetes medications, known as dipeptidyl peptidase-4 (DPP-4) inhibitors. A version sold as Janumet combines Januvia and metformin for diabetics who do not gain glycemic control from the single medication.
Januvia Cancer Lawyers
Marc J. Bern & Partners and its professional team are investigating potential Januvia pancreatic cancer lawsuits, and there are no fees or expenses unless a recovery is obtained.
Since it was introduced, Januvia has quickly grown to become one of the top selling drugs in the country and among the best sellers for Merck, a global pharmaceutical company.
Januvia and Janumet are among a new breed of medications for treatment of type-2 diabetes, along with Byetta and Victoza, which have been linked to serious and potentially life-threatening cancer side effects that may result from chronic pancreatitis.
Following a number of adverse event reports submitted over the first few years Januvia was on the market, the FDA required an update to the medications warning label in September 2009, providing information about the link between Januvia and pancreatitis.
In February 2012, the FDA issued a warning letter to Merck over their failure to conduct required testing on the risk of pancreatitis from Januvia and Janumet side effects. Although Merck promised to conduct a three month study on Januvia’s pancreatic safety by June 2011, the drug maker failed to follow through.
In March 2013, the FDA launched an investigation into the potential link between pancreatic cancer and Januvia, after a study confirmed that use of the medication may double the risk of hospitalization due to pancreatitis and cause pre-cancerous cellular changes called pancreatic duct metaplasia, which may ultimately lead to pancreatic cancer.
Despite clear signs about the potential impact of Januvia and Janumet on the pancreas, Merck has failed to adequately research the potential health problems or provide warnings about the risk of pancreatic cancer.
Januvia Pancreatic Cancer Lawsuit Allegations
Chronic pancreatitis poses a substantial risk of pancreatic cancer following Januvia or Janumet use, yet adequate information has not been provided to consumers or the medical community about the potential risk.
Former users of Januvia and Janumet diagnosed with pancreatic cancer may be entitled to financial compensation as a result of Merck’s decision to place their desire for profits before consumer safety.
According to allegations raised in Januvia lawsuits and Janumet lawsuits, Merck has:
- Failed to adequately warn about potential side effects of Januvia and Janumet;
- Failed to advise physicians about the importance of monitoring for first signs of changes to the pancreas, which may have helped users identify chronic asymptomatic pancreatitis that ultimately led to cancer following Januvia or Janumet;
- Failed to issue a Januvia recall after it became apparent that the risks outweigh the benefits provided over other, safer alternative diabetes medications;
Januvia Class Action Lawyers
Marc J. Bern & Partners and its experienced team of product liability lawyers are reviewing potential Janumet and Januvia class action lawsuits, as well as individual injury lawsuits for those diagnosed with pancreatic cancer.
Potential litigation may also be available for individuals diagnosed with thyroid cancer or other forms of cancer, as well as Januvia wrongful death lawsuits for families of individuals who have died for injuries associated with the pancreas.
All lawsuits are reviewed by Marc J. Bern & Partners’ professional team of Januvia lawyers on a contingency fee basis, which means there are no fees or expenses unless a recovery is obtained. However, every case does have a deadline or statute of limitations, so it is important to review any potential Januvia case as early as possible.